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A series of muscarinic antagonists were screened as potential receptor imaging agents. (+)2~t-tropanyl 
benzilate (TRB), N-methyl-4-piperidyl benzilate (NMPB) and several analogs amenable to labeling with 
positron emitting isotopes were evaluated for muscarinic binding to mouse brain tissue/n vitro and ex 
vivo using [3 H]quinuclidinyl benzilate as the probe. The in vitro assay directly compared the innate binding 
affinities of the compounds. The rank order of binding (IC50) was TRB (0.7 nm), QNB (0.8 nm), scopolamine 
(1.3 nm) and NMPB (1.6 nm). The ex vivo assay was used to gain information regarding the pharma- 
cokinetics and brain penetration of the compounds in live animals. Ex  vivo results demonstrated that TRB 
was rapidly taken up into the brain and was equipotent with QNB in occupying muscarinic binding sites 
at early time points, but TRB binding decreased twice as fast over time as QNB binding. The results 
suggest TRB would be a good candidate for radiolabeling and further study. 
Introduct ion  
As part of an effort to develop new muscarinic 
receptor (mAChR) imaging agents for study of the 
central muscarinic cholinergic system using positron 
emission tomography (PET), we sought a method to 
allow screening of potential ligands in unlabeled 
form. It would be desirable if the screen yielded 
information about the penetration and retention of 
ligands in the brain in vivo as well as compare their 
in vitro binding affinities for the mAChR. The screen- 
ing procedure would be applied to a group of potent, 
centrally active muscarinic antagonists and analogs 
that could be labeled with high specific activity 
carbon-ll  or fluorine-18 (Fig. 1). It was hoped that 
a combination of in vitro and e x  vivo assays (Cho et 
al., 1986; Sethy et  al., 1987) would provide answers 
to these questions and allow selection of promising 
candidates without resorting to expensive and time 
consuming radiosynthesis of each compound under 
initial consideration. 
M a t e r i a l s  and M e t h o d s  
Drugs  
Samples of (+)-2~-tropanol, nor-(+)-2ct-tropanyl 
benzilate (nor-TRB) and nor-(+)-2~t-tropanyl 
diphenylfluoroacetate (TRDFA) (Atkinson et  al., 
1983) were kindly provided by Dr Edward R. 
Atkinson. (+)-2~t-Tropanyl benzilate (TRB) 
(Atkinson et  al., 1977), 4-piperidyl benzilate (PB) 
(Biel et  aL, 1961), N-methyl-4-piperidyl benzilate 
(NMPB) (Biel et  aL, 1961) and ( _ )  quinuclidinyl 
benzilate (QNB) (Meyerhoffer, 1972; Kadin and 
Cannon, 1962) were prepared by standard literature 
procedures involving base catalyzed trans- 
esterification of the respective aminoalcohols with 
methyl benzilate. Norscopolamine- HCI was prepared 
from scopolamine (Schmidt et  al., 1965). The follow- 
ing drugs were obtained commercially: ( - )a t ropine 
sulfate. H20 (Aldrich), scopolamine. HBr. 2H20 
(Sigma) and [3H]QNB (specific activity 33 Ci/mmol, 
DuPont NEN). N-(2-Fluoroethyl)-4-piperidyl 
benzilate (FEPB) and N-(2-fluoroethyl)nortropanyl 
benzilate (FENTRB) were prepared by reacting 
PB and nor-TRB respectively, with 2-fluoroethyl 
iodide and K2CO3 in refluxing acetonitrile, and 
purified by flash chromatography (SiO 2, 20:1 : 1 
CH2 C12: MeOH: Et3 N). 
In vitro assay 
Female CD mice (24-30 g, Charles River) were 
killed by decapitation under ether anesthesia. Brains 
were rapidly removed and the cerebellum discarded. 
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Fig. 1. Structures of ligands. 
The remaining brain tissue was stored at -80°C  
until used. For the assay, each brain was thawed 
and homogenized in 3mL of ice-cold 50mM 
sodium-potassium (Na-K) phosphate buffer (pH 
7.4) containing 10 mM EDTA. The homogenate was 
kept on ice for 30 min and then centrifuged at 
48,000g for 10 min. The pellet was resuspended in 
5 mL of Na-K phosphate buffer. Protein concen- 
tration was determined using the Bradford assay 
(standard: bovine serum albumin). Protein concen- 
tration of the homogenate was 6-7 #g/#L. To assay 
the inhibition of [3H]QNB binding to brain tissue, 
triplicate samples of 50 #L of homogenate in 50 mM 
Na-K phosphate buffer containing 0.5 nM [3H]QNB 
with and without varying concentrations of drugs 
were used. A minimum of ten different concen- 
trations of each drug were used. Nonspecific binding 
was also determined in triplicate by including 1 ttM 
atropine in the assay. The entire assay was repeated 
at least twice with each drug. The assay was initiated 
by addition of homogenate to yield a final volume of 
2.0mL and incubated at room temperature for 
60 rain. The assay was terminated by addition of 
3.0 mL of ice-cold buffer followed by an immediate 
vacuum filtration using glass fibre filters (S&S ~ 32). 
Each filter was washed immediately and rapidly with 
3 x 3.0 mL of ice-cold buffer and transferred to a 
scintillation vial. After adding cocktail (3.0 mL) the 
vials were stored in the dark for 12h and then 
counted (58% efficiency). The IC50 for each com- 
pound is the average of at least two separate studies 
conducted in triplicate. The IC50 values were deter- 
mined from plots of ligand concentration vs percent 
inhibition of radiotracer binding and are tabulated in 
Table 1. 
Ex vivo assay 
Four mice were injected with drug dissolved in 
0.1 mL of 10% EtOH/saline vehicle. Control mice 
were injected with an equal volume of vehicle alone. 
Drug dosages ranged from 1 x 10 -7 to 
1 x 10-Smol/kg. The dosages of _QNB were dou- 
bled to compensate for the presence of the inactive 
enantiomer. At designated times, the mice were killed 
as above, the brains were rapidly removed, and 
cerebellum discarded. Each brain was individually 
frozen at -80°C  until used. Assays were conducted 
Table 1. IC5o values for various mAChR 
ligands obtained from competitive binding 
assays using [3H]QNB in mouse brain 
homogenates 
Drug ICso (nM) 
QNB 0.8 + 0.2 
Scopolamine 1.3 _ 0.3 
Nor-scopolamine 6.9 + 0.9 
PB 17.3 + 2.7 
NMPB 1.8 + 0.I 
FEPB 6.4 + 0.4 
TRB 0.7 + 0.3 
nor-TRB 1.3 + 0.4 
TRFDA 8.5 _+ 1.0 
FENTRB 2.5 + 0.2 
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within 2 weeks of sacrifice. Immediately prior to 
assay, each brain was thawed and homogenized 
individually in 4mL of 50mM Na-K phosphate 
buffer, pH 7.4. Homogenates were stored on ice 
(< 10 min) until added to the assay. Protein concen- 
tration was determined as above; concentrations 
ranged from 6-11 #g/#L. The assay was conducted 
as above except that homogenate incubation was 
carried out at 37°C for 30 rain and each brain was 
assayed in quadruplicate with and without 1 #M 
atropine. The counts were corrected for background 
and normalized for protein concentration. Binding 
levels are expressed as cpm/#g protein. 
Results and Discussion 
To the best of our knowledge, these in vitro and ex 
vivo binding studies of TRB, NMPB and their anal- 
ogs provide the first direct comparisons between these 
potent central muscarinic antagonists. No receptor 
binding studies have been reported for TRB or its 
analogs. Our attention was drawn to these com- 
pounds by live animal pharmacological studies which 
indicated very high potency (fourfold greater than 
QNB) and rapid onset of central effects for TRB and 
some of its analogs (Atkinson et al., 1977). The 
N-fluoroethyl analogs FENTRB and FEPB have not 
been examined previously although a structurally 
similar quaternized N-fluoroethyl 3-tropanyl ben- 
zilate is reported to have potent peripheral anti- 
cholinergic actions (Bauer and Fugner, 1986). 
Extensive pharmacological data on NMPB have 
been collected (Kloog and Sokolovsky, 1977; Soko- 
lovsky et al., 1980) and studies directly comparing 
in vitro binding of NMPB with QNB and scopol- 
amine are available (Rehavi et al., 1978). The 
inclusion of these reference ligands in our test 
procedures helped to assess the validity of the results 
obtained. 
In vitro assay: structure-binding relationships 
IC50 values were determined for each ligand by 
means of traditional, competitive binding assays. 
Values for QNB and scopolamine were also obtained 
for comparison. The results are compiled in Table 1. 
The values for NMPB, TRB, scopolamine, FENTRB 
and nor-TRB were similar in magnitude to those of 
QNB. 
Although TRB and NMPB had similar ICs0 values 
(0.6 and 1.8 nM respectively), the effects of de- 
methylation were quite different. In the piperidyl 
series, demethylation decreased the binding affinity 
by an order of magnitude whereas in the tropanyl 
series, demethylation only reduced binding affinity by 
half. Replacement of N-methyl by N-fluoroethyl in 
TRB and NMPB reduced the binding by a factor of 
approximately 3 in each case. In other studies, the 
N-propyl, N-cyclopropylmethyl and N-allyl tropanyl 
derivatives showed peripheral effects comparable to 
TRB and nor-TRB (Atkinson et al., 1977). These 
Table 2. Percent inhibition of control 
[3H]QNB binding 45 min after/n vivo drug 
injection. Drug concentration was 
1 × 10-Smol/kg 
Drug Percent inhibition 





results suggest that there is some steric tolerance of 
the receptor binding site towards N-substitution in 
the tropanyl series. 
The fluoro analog TRFDA had an ICs0 value of 
8.5 nm, however the position of fluorine attachment 
may be sensitive to hydrolysis to produce TRB. 
Further studies are necessary to establish whether the 
measured value represents the true binding affinity of 
TRFDA or is an overestimation caused by in situ 
formation of TRB from TRFDA. 
Ex vivo assay 
To assess brain penetration of the compunds, an ex 
vivo assay patterned on that used by Cho et al. (1986) 
and Sethy et al. (1987) was conducted. This ex vivo 
assay consisted of injection of unlabeled ligand into 
an animal followed by sacrifice and use of an in vitro 
binding assay to measure residual [3 H]QNB binding 
to brain homogenates. Several types of studies were 
performed: determination of effect of ligand and dose 
on receptor occupancy, and effect of time on receptor 
occupancy. 
Effect o f  ligand and dose on receptor occupancy 
Several ligands with low IC5o values were initially 
examined in the ex vivo assay at a dose of 
1 x 10 -5 mol/kg, a pharmacologically active dose for 
NMPB (Sokolovsky et al., 1980). The percent in- 
hibition of control [3H]QNB binding at 45 min for 
TRB, nor-TRB, NMPB and scopolamine are sum- 
marized in Table 2. TRB occupied the most recep- 
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Fig. 2. The percent inhibition of contro! [3H]QNB binding 
vs ligand identity and dose after i.v. administration of 
ligands to mice and sacrifice at 45 rain. 
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tors, NMPB the least and scopolamine binding was 
intermediate. TRB and nor-TRB binding were nearly 
identical, suggesting similar brain penetration and 
retention for these two compounds. This further 
emphasizes the close biological resemblance between 
TRB and nor-TRB indicated in this work by the IC50 
values and by the peripheral pharmacology data 
previously reported (Atkinson et al., 1977). 
The range of doses tested in the ex  vivo assay was 
extended from 1 x 10-Smol/kg to 1 x 10-Tmol/kg 
for TRB, NMPB and scopolamine. The results are 
depicted in Fig. 2. TRB inhibited more [3H]QNB 
binding than either NMPB or scopolamine at doses 
ranging from 1 x 10 -5 to 1 x 10 -6 mol/kg. The low- 
est detectable binding varied with ligand identity and 
apparently can be as low as 1 x 10-Tmol/kg as 
observed for TRB. As the assay was conducted 
at 37°C for 30min it is probable that a portion 
of the ligand bound in vivo dissociated during 
the incubation; the measured value of [3H]QNB 
binding inhibition is therefore a lower limit for ligand 
receptor occupancy at the time of sacrifice. 
Effect o f  time on receptor occupancy 
The effect of time on receptor availability was 
compared for QNB and TRB. The results, plotted as 
percent inhibition of control [3H]QNB binding vs 
time are shown in Fig. 3. In this study, mice were 
injected either with QNB or TRB (1 x 10 -5 mol/kg) 
and sacrificed at designated times. The binding level 
for drug is expressed as a fraction of the binding level 
for controls. Both TRB and QNB demonstrated 
almost complete receptor occupancy at 2 min post 
injection. While the percentage of receptor vacancy 
increased with time for both compounds, the rate of 
increase was about twice as fast for TRB compared 
to QNB: t~/2 = 113 min for TRB and 234min for 
QNB (correlation coefficients of In Co/Ct vs time were 
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Fig. 3. Inhibition of [3H]QNB binding at various time 
intervals after i.v. administration of 1 x 10 -5 mol/kg doses 
of TRB or QNB to mice. 
0.992 for TRB and 0.986 for QNB). It is noteworthy 
that these data are similar to the time course of 
anti-tremorine (central) effects of QNB and TRB 
previously reported (Atkinson et al., 1977). 
Evaluation of receptor-based agents employing 
only in vitro studies suffers because normal phys- 
iological compartments and barriers are disrupted 
and tissue homogenization may expose more binding 
sites than are accessible in vivo. For example, striking 
differences between [3H]spiperone binding to in vitro 
homogenates, in vitro tissue slices and in vivo tissue 
samples have been described in normal and dopamine 
denervated rat striatal tissue (Bennett and Wooten, 
1986). Although the ex  vivo assay does not dis- 
tinguish binding of parent drug from binding of 
active metabolites, it does provide a more realistic 
assessment of radiopharmaceutical potential than 
in vitro binding assays alone. The combination of in 
vitro competitive binding assays and estimation of 
in vivo receptor occupancy does not generate all the 
information needed to evaluate a potential receptor 
imaging agent, but it helps narrow the list of potential 
receptor-based agents without the need for prior 
radiosynthesis. 
C o n c l u s i o n  
In vitro competitive binding assays have shown 
that several piperidyl and tropanyl bcnzilates have 
binding affinities for the mAChR comparable to 
QNB and scopolamine. Radiolabeled forms of QNB 
(Eckelman et al., 1984) and scopolamine (Frey et al., 
1987; Mulholland et al., 1988) have been used to 
image the mAChR in human brain. These piperidyl 
and tropanyl benzilates may also serve as imaging 
agents. E x  vivo assay results indicate that TRB 
occupies more receptors than the other ligands exam- 
ined and appears to be equipotent with QNB while 
possessing a faster rate of clearance from the brain. 
The accumulated evidence points to TRB as a likely 
candidate for radiolabeling and further evaluation as 
a PET agent for mAChR imaging. 
Of considerable importance is that the ex  vivo assay 
can be employed to (1) demonstrate CNS localization 
of a ligand or its active metabolites (2) rank ligands 
in terms of in vivo binding potency and (3) assess 
receptor clearance rates. Thus, the combination of 
both in vitro and ex  vivo assays is beneficial in 
selection of potential imaging agents. 
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